Repositioning Candidate Details

Candidate ID: R0978
Source ID: DB06311
Source Type: investigational
Compound Type: small molecule
Compound Name: Darapladib
Synonyms: Darapladib
Molecular Formula: C36H38F4N4O2S
SMILES: CCN(CC)CCN(CC1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F)C(=O)CN1C2=C(CCC2)C(=O)N=C1SCC1=CC=C(F)C=C1
Structure:
DrugBank Description: --
CAS Number: 356057-34-6
Molecular Weight: 666.78
DrugBank Indication: Investigated for use/treatment in atherosclerosis.
DrugBank Pharmacology: --
DrugBank MoA: Darapladib is a selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2 is an enzymatic upstream mediator of inflammatory processes. Evidence from experimental settings show that the breakdown products from oxidized low density lipoprotein C (LDL-C)such as lysophosphatidylcholine species and oxidized nonesterified fatty acids are pro-inflammatory and pro-apoptotic. These products are suspected to cause athlerosclerosis progression and plaque vulnerability, which leads to increased risk of cardiovascular problems.
Targets: Cytosolic phospholipase A2
Inclusion Criteria: Therapeutic strategy associated